Growth equity firm Tercera releases its fifth annual Tercera 30, highlighting the software and AI

ecosystems with the greatest potential for IT service firms.

CHICAGO, Oct. 16, 2026 /PRNewswire/ -- Tercera, an investment and advisory firm for AI and technology service firms, today released the 2026–2027 Tercera 30. The Tercera 30 is an annual ranking of the top software and AI vendors for IT services firms and the partner ecosystems that offer the greatest potential for services growth. The vendors and trends highlighted in this fifth anniversary edition reflect the shift happening across IT services in the new AI era.

Eleven vendors are new or have boomeranged back onto this year's Tercera 30 list, underscoring how quickly the AI and software partner landscape is changing. Three new vendors – Anthropic, OpenAI and Palantir – join the Market Anchors category, vendors with large TAMs, large clients and broad platforms. That is the most movement in this category ever.

This year's Tercera 30 report also features redesigned Domain Leaders and Builders categories, reflecting how IT services partners are increasingly specialized by industry and required to have data and AI depth.

In Tercera's July 2026 IT services survey of 378 technology services leaders, only 5% of firms focused on a single software partner, down from 10% last year. Firms are increasingly moving from single-vendor platform implementations to orchestrating data, systems and agents around domain processes and clear business outcomes.

"The services market is radically shifting," said Chris Barbin, CEO of Tercera. "The vendor landscape is in chaos, traditional partner motions are at risk, and new growth opportunities are presented daily – often at the intersection of data, AI, software and services."

Introducing 2026–2027 Tercera 30

Market Anchors. Large vendors that can support a dedicated services business: Databricks, Snowflake, Anthropic, ServiceNow, OpenAI, Palantir, Microsoft, Google Cloud, AWS, and Salesforce.

Domain Leaders. Platforms that can serve as pillar partners for firms specializing in an industry or function: Oracle, SAP, Guidewire, Atlassian, Workday, HubSpot, OneStream, Saviynt, commercetools, and Ada.

Builders. Data and AI vendors representing different layers of the AI stack: Nvidia, VAST Data, MongoDB, Cohere, Dynatrace, Glean, Dataiku, Quantexa, Denodo, and Credo AI.

Vendors in the Tercera 30 were selected through a rigorous data analysis, interviews with software executives, input from analysts and bankers, and insights from Tercera's annual services survey. More info on the methodology can be found here.

Services leaders should use this report to assess partner strategies, identify the most promising AI partner ecosystems, and anticipate where demand is heading. Download the full report here.

About Tercera

Tercera is an investment and advisory firm focused on helping AI and technology services businesses grow. Its team of experienced operators provides capital, counsel, and connections to help leaders build and scale their firms.

SOURCE Tercera

Share this article

MARIETTA, Ga., Oct. 16, 2026 /PRNewswire/ -- A new era of strategic airborne command and control capability for the U.S. Navy has officially begun with Lockheed Martin (NYSE:LMT) delivering a C-130J-30 Super Hercules aircraft destined to become the future of the Take Charge and Move Out (TACAMO) mission, at the company's Marietta, Georgia, facility on Oct. 15.

The C-130J-30 Super Hercules will be modified into the E-130J Phoenix II, the Navy's next‑generation TACAMO mission platform, fulfilling an added mission for the Super Hercules. TACAMO is the U.S. Navy's airborne nuclear command‑and‑control support mission.

The Super Hercules provides the Navy with a domestically produced, reliable, long-endurance, four-engine platform with the proven performance to successfully carry out the TACAMO mission. With advanced avionics, increased power, greater range, fuel efficiency and payload capacity, the C‑130J‑30 delivers the capabilities and endurance this critical mission demands.

"This delivery marks a historic milestone for the U.S. Navy, Lockheed Martin, and the nation's strategic communications network," said Trish Pagan, vice president of Lockheed Martin's Air Mobility & Maritime Missions. "The C-130J-30 Super Hercules continues to evolve and adapt to the needs of our customers, carrying the proven reliability of its lineage while transforming into a new, strategic mission set. It is built to deliver the capabilities our joint force demands and built to last through any operational challenge."

The delivery re-establishes the link between the TACAMO mission and the Hercules family. For three decades, the EC-130Q variant served as the Navy's TACAMO platform, flying the mission successfully from 1963 until 1993. The new Super Hercules builds on that legacy while adding advanced avionics, communications and survivability enhancements.

"The C-130J platform has a storied history supporting our strategic communications mission, and accepting this first C-130J-30 marks an exciting new chapter," said U.S. Navy Capt. Roger Davis, Airborne Strategic Command, Control and Communications program manager (PMA-271). "Lockheed Martin's delivery of this battle-proven airframe provides the structural and performance backbone our mission requires as we transition into mission systems integration to field the E-130J Phoenix II."

As part of the Super Hercules' transformation, the aircraft will be transferred to Northrop Grumman, the mission systems integrator, where the E-130J TACAMO industry team will complete the conversion that will see the airframe enter service as the E‑130J Phoenix II.

About the C-130J Super Hercules

The C-130J Super Hercules is the latest generation of the legendary C-130 Hercules. Built with advanced avionics, increased range and speed, and enhanced survivability, the C-130J is certified across 20 different mission sets — including airdrop, search and rescue, firefighting, medevac, ISR, special operations, among others. It is the only tactical airlifter with a global fleet of more than 570 aircraft and continues to serve as the backbone of air mobility worldwide.

For additional information, visit our website: https://www.lockheedmartin.com/en-us/products/c130.html.

About Lockheed Martin

Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at Lockheedmartin.com.

SOURCE Lockheed Martin Aeronautics

Share this article

New Bronco Bound partnership offers a direct path to a bachelor's degree, guaranteed scholarships and more

GRAND RAPIDS, Mich., Oct. 16, 2026 /PRNewswire/ -- A GRCC Raider today. A WMU Bronco tomorrow. For Grand Rapids Community College students dreaming of earning a bachelor's degree, that next step is about to become a lot more certain.

Through a new partnership called the Bronco Bound Guarantee, students who earn an associate degree at GRCC will be guaranteed admission to Western Michigan University, along with an annual scholarship ranging from $1,000 to $4,500 for eligible students.

Leaders from both institutions will make the partnership official during a signing ceremony at 3 p.m. Friday, Oct. 16, at GRCC's Applied Technology Center, Secchia Piazza, on the college's main campus in Grand Rapids. Media are invited to attend.

"Strong partnerships create strong pathways for students. This agreement reflects a shared commitment to making higher education more accessible, affordable and connected," said GRCC President Dr. Kathryn A. Rogalski. "We are proud to partner with Western Michigan University, an institution that recognizes the quality of a GRCC education and the strong foundation our students bring to their next chapter. Together, we are creating more opportunities for students to achieve their educational goals and build a brighter future for themselves and our communities."

The Bronco Bound Guarantee is designed to take some uncertainty out of transferring from community college to a four-year university.

"Having led a community college, I know the important role these institutions play in helping students discover their potential and pursue their goals," said WMU President Russ Kavalhuna.

"Our partnership with Grand Rapids Community College builds on that foundation. We want students to arrive at Western knowing they belong here, find opportunities to put their learning into practice and have the support to thrive, graduate, and build meaningful careers."

In addition to guaranteed admission, qualifying GRCC students will have their WMU application fee waived and receive scholarship consideration automatically, with eligible students guaranteed an annual award of $1,000 to $4,500.

Students will also have access to dedicated transfer advising and recommended academic plans to help them make the most of their credits. Those who can complete an associate degree through an approved transfer guide or program agreement will have their defined credits apply toward the corresponding WMU degree requirements, avoiding the frustration of losing credits along the way.

And students won't have to wait until their first day at WMU to begin feeling like Broncos.

Prior to admission, eligible students will enjoy early access to university resources and campus experiences, including free admission to WMU sporting events, excluding hockey.

The partnership is about more than providing a route to admission. It is also about helping students make a successful transition into university life, connect with the Bronco community and take advantage of distinctive academic programs and experiential learning opportunities.

The partnership also recognizes the importance of completing a GRCC credential. Through a no-cost reverse transfer process, students who continue their education at WMU can have eligible university credits transferred back to GRCC to help them earn an associate degree.

GRCC and WMU will continue working together beyond the signing ceremony, with WMU participating in at least one transfer-focused event each semester and both institutions reviewing student enrollment and achievement data to strengthen the partnership.

For GRCC students, Bronco Bound means the journey toward a bachelor's degree can begin with greater confidence, knowing their next opportunity is already within reach.

About Grand Rapids Community College

GRCC was established in 1914 — Michigan's first community college — and is focused on making college education accessible and affordable. Classes are scheduled weekdays, evenings and Saturdays in Grand Rapids, Holland and online. We offer traditional liberal arts and occupational career pathways, adult education courses and skilled training courses and apprenticeships.

About Western Michigan University

WMU students are individuals who are truly unique. At Western, we celebrate the passions that drive students and the possibilities that inspire them. For us, a degree is a pursuit of purpose where students are empowered to learn and where an experience-driven education leads to a meaningful career. Broncos prosper. Nine out of 10 graduates are employed quickly, working in their field in jobs they like. WMU students make their mark on the world—Grammy recipients, Super Bowl champions, doctors, teachers, pilots and countless others have flourished here. Western is the place where students become the best version of themselves. WMU is a public research university, offering a range of undergraduate, graduate, and doctoral programs to more than 17,000 students. Learn more at https://wmich.edu/

Media Contacts:

Lyndsie Post

Executive Director of Marketing & Communications

(616) 234-4213

[email protected]

Paula M. Davis

Associate Vice President for Strategic Communications

(269) 387-8411

[email protected]

SOURCE Grand Rapids Community College

Share this article

Launched in April 2026, BC Engine has reached a major milestone in cumulative rewards, strengthening its role as a core value-sharing mechanism within the BC.GAME ecosystem

BELIZE CITY, Belize, Oct. 16, 2026 /PRNewswire/ -- BC.GAME - the award-winning global online entertainment platform - can announce that its BC Engine has surpassed 10 million BCD in cumulative rewards, equivalent to more than US$10 million, just six months after its launch on April 8, 2026.

The milestone highlights the rapid growth of BC Engine, which has evolved from an hourly reward mechanism into an increasingly important pillar of the BC.GAME ecosystem, connecting $BC holders, platform activity, and gaming partners through recurring value distribution.

From launch to $10 million in six months

Since its introduction, BC Engine has recorded consistent growth in cumulative rewards.

On May 28, participating $BC holders had earned more than 2.1 million BCD. By July 28, cumulative rewards had exceeded 5 million BCD, reaching 8.6 million BCD by September 18.

Now, just six months after launch, the figure has surpassed 10 million BCD, representing nearly fivefold growth since late May.

BC Engine allows eligible $BC holders to earn BCD rewards through hourly settlement rounds. The reported US$10 million represents rewards already earned through completed settlements, rather than projected returns or changes in $BC's market price.

Building a stronger BC.GAME ecosystem

Beyond the milestone itself, BC Engine is becoming a key component of BC.GAME's long-term ecosystem strategy.

Unlike conventional promotional rewards, BC Engine connects platform activity with recurring value distribution, creating ongoing incentives for participation and strengthening the utility of $BC.

Through the introduction of Engine Nodes, partners including BC Originals, Croco Gaming and BETBY, have become part of the expanding reward ecosystem, connecting different gaming products and providers through a shared value distribution mechanism.

For users, BC Engine provides recurring rewards and transparent settlement records. For ecosystem partners, it creates deeper connections with the platform and its community. Together, these mechanisms are designed to strengthen long-term engagement, build trust and support a more interconnected gaming ecosystem.

Supporting BC.GAME's global expansion

BC Engine's growth comes alongside BC.GAME's continued international expansion.

In 2026, BC.GAME strengthened its regulated presence in Mexico and partnered with Mexican football legend Guillermo "Memo" Ochoa as a brand ambassador, reinforcing its localization strategy in Latin America.

As BC.GAME continues to develop its international operations, BC Engine serves as an increasingly important mechanism connecting platform growth, $BC utility and ecosystem participation.

Surpassing US$10 million in just six months marks a significant step toward BC.GAME's vision of building a more connected, participation-driven gaming ecosystem.

Adrian Chen, Senior Legal Counsel at BC.GAME, said: "Achieving 10 million BCD in rewards in the first six months of the BC Engine demonstrates the success and rapid growth of our rewards programme and adoption amongst players. We look forward to rewarding even more BCD in the coming months as we continue to scale our ecosystem globally."

About BC.GAME

BC.GAME is a global online gaming and entertainment platform offering casino, sportsbook and digital asset-based products across international markets where permitted.

Since 2017, BC.GAME has developed a crypto-native entertainment ecosystem focused on product innovation, community participation and global partnerships. Its native token, $BC, powers ecosystem utilities including BC Engine, which provides recurring BCD rewards to eligible participants.

For more information, visit https://bc.game/bc.

SOURCE BC.GAME

Share this article

FEATURING BRAND-NEW DESIGNER GOODS PRICED UP TO 80% OFF + EXCLUSIVE CURATED COLLECTIONS FROM: Andrew Bui, Jason Campbell, Kathy Hilton, Nicky Hilton Rothschild + Paris Hilton, J.Logan Horne, Natalie Kates, Robyn Mowatt, Lucy Sykes, Timo Weiland, Ezra Williams, and Donna D'Cruz + Tommy Silverman

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Housing Works, the New York City non-profit organization dedicated to supporting those impacted by homelessness and HIV/AIDS, is proud to announce the return of its annual Fashion for Action fundraiser. This year's event will take place November 12-14, 2026, at Housing Works' flagship Chelsea Thrift Shop and Housing Works' rebranded online shop, RefindNYC with all proceeds directly benefiting the organization's lifesaving services and advocacy.

Bringing together leaders in fashion, media, and entertainment, the three-day shopping event will kick off on November 12 with a festive reception with music by Mia Moretti, followed by VIP and general admission shopping opportunities. The sale will then be free and open to the public on November 13 and 14, offering shoppers access to an unparalleled selection of designer merchandise at exceptional prices.

Fashion for Action will feature brand-new designer apparel, handbags, shoes, accessories, jewelry, beauty products, and more, all generously donated by leading fashion brands priced at 50-80% below retail prices. The event will also showcase exclusive curated collections featuring one-of-a-kind donations selected by prominent tastemakers and cultural figures that include: Andrew Bui, Jason Campbell, Kathy Hilton, Nicky Hilton Rothschild + Paris Hilton, J. Logan Horne, Natalie Kates, Robyn Mowatt, Lucy Sykes, Timo Weiland, Ezra Williams, and Donna D'Cruz + Tommy Silverman. There will also be a special "Passport to Style" collection featuring an array of international designers that celebrate the global influences of fashion and culture with looks by Anohki, Obida, Emote, and Olivia Dar.

This year's event also includes a dedicated lineup of Housing Works leaders serving as Co-Chairs: Paper Magazine Editor, Mickey Boardman; stylist Jason Bolden; interior designer Adair Curtis; gallerist Natalie Kates, who is also serving as an event curator; and stylist Kesha McLeod.

Opening Night tickets are available now. Proceeds from Fashion for Action directly support Housing Works' integrated services and advocacy efforts addressing homelessness, HIV/AIDS, and health equity throughout New York City.

Special thanks to our event sponsors: Fernway; Forager Project, a dairy-free creamery; LabCorp; Lamb Insurance Services; Sarah Keech; and THE HUNGER GAMES: SUNRISE ON THE REAPING.

About Fashion for Action

Fashion for Action began in 2004 with founding chairs Kevin Harter and Michael Carl at the helm. Past event chairs have also included Iman, Andre Leon Talley, Bethann Hardison, Anna Sui, Billy Porter, John Varvatos, Thom Browne, Francisco Costa, Dree Hemingway, Marc Jacobs, Natalie Joos, Derek Lam, and Rachel Roy. Together with the support of the fashion and beauty community, the benefit has grown to raise millions towards the fight against HIV/AIDS in New York City.

About Housing Works

For over 30 years, Housing Works has fueled the fight to end HIV and Homelessness through fashion. Our Thrift Shops and signature events directly benefit our trailblazing work in grassroots activism, healthcare, and housing. Housing Works led the way during the height of the AIDS crisis in New York City, and continues to lead advocacy efforts in support of health equity and social justice.

For more information about Housing Works, visit housingworks.org. Join Housing Works on Facebook. Follow Housing Works on Instagram.

SOURCE Housing Works

Share this article

- Two Powertrains, Including the TX 500h Performance Hybrid

- Spacious Third-Row Legroom and Generous Cargo Space of 20.2 Cubic-Feet Behind the Third Row

- Lexus Safety System+ 3.0 Standard on All 2027 TX Models

- Matador Red Mica Offered as an Exterior Color for Non-F SPORT Models

- TX 550h+ Plug-In Hybrid (PHEV) Discontinued for 2027 Model Year

- Starting MSRP of $58,890 (includes DPH)

PLANO, Texas, Oct. 16, 2026 /PRNewswire/ -- For the 2027 model year, the Lexus TX receives minor changes and continues to offer customers style, utility, and comfort without compromising on innovative technology and dynamic performance.

The 2027 TX sees Matador Red Mica return as an exterior color option for non-F SPORT models (after being introduced on those models for 2026), while the TX 550h+ plug-in hybrid (PHEV) model is discontinued. There are minor changes and revisions to the TX 350 models' vacuum brake booster tuning and brake hold feature, while the TX 500h now wears "AWD" badges instead of the "DIRECT4" pieces used for 2026. The 20-inch aluminum wheels on the 2027 Lexus TX 350's Premium grade adopt a darker gray finish, and red-painted brake calipers are a new option on F SPORT grades.

The TX is offered in seven grades—Standard, Premium, Luxury, F SPORT Handling, F SPORT Performance Premium, and F SPORT Performance Luxury—and with two powertrains: the gas TX 350 and the TX 500h hybrid electric vehicle (HEV). For a full breakdown of the standard and available features by grade, please see the TX Specifications.

The Global Architecture-K (GA-K) Platform

Like the RX and NX, the 2027 TX rides on the GA-K platform, which offers optimal weight distribution and facilitates the SUVs' dynamic and agile driving performance. The platform reduces noise vibration and contributes to a smooth and serene ride with exceptional comfort. It also enables precise suspension movement, straight-line stability, and steering responsiveness so that the car and driver act in harmony – this is what the brand calls the LDS.

LDS has served as the guiding philosophy behind the development of Lexus vehicles. It blends both luxury and performance to deliver an exceptional and engaging driving experience. On the TX, LDS is expressed through predictable, linear responses according to the driver's intentions.

To achieve the desired ride comfort and quietness, focus was placed on strengthening the TX's body rigidity while minimizing increases in weight. Body adhesives have been placed in optimal locations to help ensure the vehicle remains composed and nimble while turning into a corner or driving on rough pavement. Other enhancements include short pitch spot welding, the introduction of a rear multi-link suspension design, and widened front and rear tracks.

To lighten the TX's body, the outer panel thickness has been fine-tuned on the side members, front door assembly, and rear door assembly. The hood and front fender material is aluminum, while the back door is steel, resulting in an optimized front-rear weight distribution.

A Powertrain to Fit Everyone's Needs

To help meet the diverse needs of Lexus customers and cater to any lifestyle, the 2027 TX will be offered with two powertrain options: a 2.4L turbocharged inline 4-cylinder on the TX350, and a 2.4L turbocharged hybrid on the TX500h.

TX 350 (FWD/AWD)

The 2.4L turbocharged inline-4 engine, also seen on the RX and NX, delivers high torque and high output, with 275 horsepower and 317 lb.-ft. of torque. To help ensure the vehicle's dynamic performance, several advanced technologies were added including: a center injection system (for more stable combustion); lightweight, spherical lipless pistons (for high-speed combustion); and a continuously variable capacity oil pump (to modify discharge volume based on running conditions).

A wide-spread and close-ratio eight-speed Direct Shift automatic transmission offers an improved shift control program for smooth acceleration and deceleration. The available electronically controlled full-time AWD system constantly varies the front-to-rear driving force distribution from 75:25 to 50:50 (depending on situation) to achieve a confident and refined driving experience.

The TX 350 is available on Standard, Premium, F SPORT Handling, and Luxury grades.

TX 500h F SPORT Performance (AWD only)

For those seeking even more power and performance, the 2.4L turbocharged Parallel Hybrid system provides 366 total system horsepower and 406 lb.-ft. of torque. The engine is matched to a six-speed automatic transmission, integrated Power Control Unit, and a 64-kW motor. At the rear, a 76-kW eAxle consisting of an inverter and motor provides near-instantaneous power to the rear wheels. The TX 500h combines all-wheel drive (AWD) and Dynamic Rear Steering (DRS), resulting in exhilarating acceleration and superb dynamic handling.

The nickel-metal hydride (NiMH) battery is mounted beneath the second row, yielding additional storage capacity and increased power to create the ultimate three-row thrill ride.

The TX 500h is available exclusively as F SPORT Performance Premium or F SPORT Performance Luxury.

Suspension

To achieve TX's refined ride quality, a MacPherson strut type front suspension was affixed to the GA-K platform. This system reduces the shock and vibration of road imperfections to facilitate smooth and linear performance. The rear's five-arm multi-link facilitates controlled steering reactions.

Adaptive Variable Suspension (AVS) (Standard on F SPORT Handling and F SPORT Performance)

TX's available AVS system enhances road handling and ride quality. AVS uses linear solenoid-type actuators to modify shock absorbers' damping force on all four wheels with near-instant adjustments that are based on driving operation and road conditions. When driving on a rough road surface, the damping force keeps a lower rating to maintain a comfortable ride. For smooth and stable performance needed when entering a turn, the damping force adjusts to a higher rating and provides enhanced responsiveness.

Braking and Steering

The TX's braking system builds upon Lexus Driving Signature fundamentals to provide a smooth, yet exhilarating drive. A vacuum brake system has been adopted on the TX 350 for refined braking control and responsiveness. For the TX 500h, the brake force is controlled by pressure regulation in the front and rear using a pressure-on-demand system and high-performance pump motor.

The TX's linear steering response and controlled movements belie the actual size of the vehicle. A standard rack assist-type Electric Power Steering (EPS) system reduces the amount of steering input needed by utilizing a new motor and reduction gear setup that is installed parallel to the steering box. Moreover, a Motor Control Unit (MCU) with an integrated motor and motor current control Electronic Control Unit (ECU) reduces the EPS' size footprint and minimizes operational noise.

Dynamic Rear Steering (DRS)

Exclusive to and standard on F SPORT Performance, DRS can provide impressive maneuverability in low-speed situations and exceptional vehicle stability in high-speed situations. During higher speed maneuvers, the rear wheels turn in the same direction as the front wheels to give clear, stable turning response. At slower speeds, the rear wheels can seamlessly turn in the opposite direction as the front wheels for seamless maneuverability.

Drive Mode Select

Drive Mode Select allows the driver to tailor their experience by selecting from a mix of available drive modes, including:

- Normal mode: Delivers a balance of driving performance and fuel efficiency by optimizing the accelerator's response.

- ECO mode: Maximizes fuel savings across all driving conditions by reducing throttle response and air conditioner operations to keep the engine speed in an efficient range.

- Sport mode: Increases the overall throttle responsiveness, resulting in sporty and responsive acceleration.

- Custom mode: Enables the driver to create a unique profile for the powertrain, chassis, and air conditioning functions. When equipped with AVS, the suspension settings also can be changed.

DIRECT4 (Standard on TX 500h)

Also seen on the RX and RZ, DIRECT4 is Lexus' all-wheel drive technology. The system orchestrates a seamless, direct application of drive force between the front and rear axles in milliseconds, thus improving handling, controllability, and feel. Body movement is also minimized for enhanced ride comfort.

With a rear eAxle, the four wheels intuitively shift drive force to deliver direct and stable handling and can provide up to 80 percent of power to the rear wheels when needed. DIRECT4 constantly varies front-to-rear driving force distribution from 100:00 to 20:80 (depending on situation) to achieve maximum grip, traction, and acceleration.

Trail Mode (Standard on TX 350 AWD, TX 500h)

Trail Mode provides integrated control of the AWD, braking, and drive force to minimize wheel slippage when driving on wet or uneven road surfaces.

Practical Elegance and Design

The 2027 TX was designed to provide functional features without compromising the luxury touches Lexus customers enjoy.

Exterior Features

As showcased with other recent Lexus vehicles, the TX's front fascia has been redefined and proudly reflects the new expression of Lexus design. The creation of the Lexus "Unified Spindle" pays tribute to Lexus' current design language while adding eye-catching and unique elements.

This sleek front-end was designed to prioritize aerodynamic performance and enhance the vehicle's stability. The TX's front spindle efficiently regulates airflow while cooling its brakes and is optimized to lower the coefficient of drag value. Other aerodynamic elements include airflow regulating fins, a roof spoiler, and rear combination lamps.

At the rear of the TX, the flared fenders accentuate the vehicle's wide track width and strong stance.

STUART, Fla., Oct. 16, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company") will host its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") on Tuesday, November 10, 2026, at 10:00 AM ET via live virtual webcast.

At the 2026 Annual Meeting, holders of Company stock as of the close of business on September 18, 2026 (the "Record Date") will be able to vote their shares electronically and submit questions during the meeting.

To participate in the 2026 Annual Meeting, such stockholders as of the Record Date should visit www.cleartrustonline.com/HIT. Guests may also access the 2026 Annual Meeting in listen-only mode. No control number is required for guests.

A replay of the webcast will be accessible on the Company's website at https://healthintech.investorroom.com/Events.

About Health In Tech

Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that aims to improve processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, managing general underwriters ("MGUs") and third-party administrators ("TPAs"). Health In Tech's platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

Investor Contact:

Health In Tech Investor Relations

[email protected]

SOURCE Health In Tech Inc.

Share this article

- ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous autoinjector for adults living with generalized myasthenia gravis (gMG) in the U.S.¹

- ZILBRYSQ now offers two self-administration options for adults living with gMG who are anti-acetylcholine receptor (AChR) antibody positive.1

- The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.2,3

- Approval is supported by data showing ZILBRYSQ bioequivalence between the autoinjector and the existing prefilled syringe, with complete dose delivery achieved for 99.8% (n=449*) of autoinjector administrations. Patients reported high satisfaction with self-injection of ZILBRYSQ using the autoinjector device.2

ATLANTA, Oct. 20, 2026 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with ZILBRYSQ® (zilucoplan).¹ The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.2,3

"This approval is the answer to a question on which we've been relentlessly focused: How do we continue to improve an already effective therapy for daily use?" said Kimberly Moran, PhD, SVP & Head, U.S. Rare Diseases at UCB. "As the first treatment to be approved as a once-daily autoinjector option for adults living with gMG in the U.S., ZILBRYSQ now provides the same therapy via another administration option. At UCB, we are committed to science and make it our point to continually help improve how people experience it."

The ZILBRYSQ autoinjector is designed to automatically deliver a pre-defined dose when activated against the skin.1,2 Prior to the autoinjector's approval, ZILBRYSQ was available as a self-administered prefilled syringe (PFS). Patients or their care partners will now have another portable treatment solution.

"For a chronic condition like gMG, having different administration options allows patients to choose the approach that best fits their individual preferences and routines," said Donatello Crocetta, Global Head of Medical Affairs and Chief Medical Officer at UCB. "From a medical standpoint, it was essential to confirm that this added administrative option didn't come at the expense of safety and efficacy. The data supporting the autoinjector's complete dose delivery show that this option continues to offer an effective treatment for patients."

The approval of the ZILBRYSQ autoinjector for self-administration is supported by data from the following studies:

- DV0012 – a Phase 1, open-label, single-center, two-period crossover study in healthy adult volunteers (n=14) which established bioequivalence of ZILBRYSQ delivered via an autoinjector compared with a PFS.2

- DV0013 – a Phase 3b open-label, multi-center study in adult patients (n=31) with gMG self-administering ZILBRYSQ via autoinjector once daily. Complete dose delivery was achieved for 99.8% (n=449*) of autoinjector administrations. Patients reported high satisfaction with self-injection of ZILBRYSQ using the autoinjector device.2 Self-administration was generally well tolerated. The most common TEAE was injection-site pain (n=3; 9.7%).2

- A human factors validation study of 100 participants† demonstrating that 90% successfully completed an injection with the ZILBRYSQ autoinjector on their first attempt without training.4

UCB expects the autoinjector to be available commercially in Q1 2027.

*Total autoinjectors used and returned.

†Participants defined as patients with gMG or those exhibiting ocular symptoms (injection-experienced and injection-naïve); caregivers (injection-experienced and injection-naïve); and healthcare professionals (HCPs).

About ZILBRYSQ® (zilucoplan)

ZILBRYSQ (a synthetic macrocyclic peptide) is a once-daily, self-administered, subcutaneous injection that works by blocking complement component 5 (C5), a protein involved in the immune-mediated damage that occurs at the neuromuscular junction in gMG.1,5 ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.¹

The precise mechanism through which ZILBRYSQ exerts therapeutic effects in gMG is unknown.

In addition to ZILBRYSQ, UCB's gMG portfolio includes RYSTIGGO® (rozanolixizumab-noli), a subcutaneously infused monoclonal antibody targeting the neonatal Fc receptor (FcRn) approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.6 With two approved medicines with distinct mechanisms of action, UCB continues to offer physicians and the U.S. gMG community a choice of targeted therapies from a single company.

The precise mechanism through which RYSTIGGO exerts therapeutic effects in gMG is unknown.

About generalized myasthenia gravis (gMG)

gMG is a rare neuromuscular autoimmune disease that has a global prevalence of 150–350 cases per 1 million people.7 People living with gMG can experience a variety of symptoms, including severe muscle weakness that can result in double vision, drooping eyelids, difficulty with swallowing, chewing and talking, as well as life-threatening weakness of the muscles of respiration.8,9

In gMG, pathogenic autoantibodies can impair synaptic transmission at the neuromuscular junction (NMJ) by targeting specific proteins on the post-synaptic membrane.10 This disrupts the ability of the nerves to stimulate the skeletal muscle and results in a weaker contraction.10 gMG can occur in any race, gender or age.8,9,11

Important Safety Information about ZILBRYSQ® (zilucoplan) in the U.S.1

ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis.

- Complete or update meningococcal vaccination (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risk of delaying therapy outweigh the risks of developing a meningococcal infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination against meningococcal bacteria in patients receiving a complement inhibitor.

- Persons receiving ZILBRYSQ are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for signs of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ZILBRYSQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ZILBRYSQ REMS.

CONTRAINDICATIONS

ZILBRYSQ is contraindicated for initiation in patients with unresolved Neisseria meningitidis infection.

WARNINGS AND PRECAUTIONS

Serious Meningococcal Infections

ZILBRYSQ, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of ZILBRYSQ treatment is contraindicated in patients with unresolved serious Neisseria meningitidis infection. Complete or update meningococcal vaccination (for serogroups A, C, W, Y and B) at least 2 weeks prior to administering the first dose of ZILBRYSQ, according to current ACIP recommendations for patients receiving a complement inhibitor. If urgent ZILBRYSQ therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Consider interruption of ZILBRYSQ in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated.

ZILBRYSQ REMS 

Due to the risk of meningococcal infections, ZILBRYSQ is available only through a restricted program under a REMS called ZILBRYSQ REMS. Under the ZILBRYSQ REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccines. Additional information on the REMS requirements is available at www.ZILBRYSQREMS.com or 1-877-414-8353.

Other Infections

Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported in patients treated with complement inhibitors.

Verdin, designer of the Dr. Verdin Baseline Assessment(TM), joins Attilio as Co-Chairman.

ST. PETERSBURG, Fla., Oct. 16, 2026 /PRNewswire/ -- Attilio announced today that Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging, has joined the company as Co-Chairman.

Verdin leads the Buck Institute, the first independent biomedical research institute in the world focused solely on aging and age related disease. Founded in Novato, California, the Institute helped build and legitimize the field now known as geroscience and has produced landmark discoveries in aging biology since its founding. Verdin has testified before the United States Congress on the science of aging and speaks widely on the subject, sharing findings directly with the public rather than keeping them inside academic journals.

As Co-Chairman, Verdin brings Attilio direct access to the research driving the field of geroscience, the biomarkers, imaging, and clinical protocols the Buck Institute uses to study aging in humans. He shapes the scientific direction behind every member's care, drawing on decades spent identifying which interventions actually extend healthy life and which do not hold up to scrutiny. That same research underlies the Dr. Verdin Baseline Assessment(TM), which Attilio offers members for $2,500.

Verdin also headlines Attilio's inaugural Longevity Event, October 29 and 30, 2026, at Stanford University and the Buck Institute for Research on Aging, alongside Dr. Laura Carstensen, Dr. Robert Waldinger of Harvard Medical School, and Dr. Dean Ornish.

"Eric is all in on this mission," said Paul A. Pagnato, CEO & Founder of Attilio. "He brings decades of research and a direct line to the Buck Institute's work. Now, as Co-Chairman, he helps shape where Attilio goes next."

Attilio Mission: Democratize access to +100Year Quality Lifespan, reaching 99% of U.S. population.

Learn more about Attilio at www.attilio.com.

About Attilio

Attilio is a Human powered AI Life Optimization Platform(TM), technology, and Stewardship built to help people live longer, healthier lives. Every membership operates under the company's Conflict-Free Standards(TM): no commissions, no revenue sharing, no self-dealing. Attilio launched in September 2026 under CEO & Founder Paul A. Pagnato, working with experts from Stanford University, Harvard University, and the Buck Institute for Research on Aging.

Media Contact

Lia Bliss, Chief Marketing Officer [email protected] https://attilio.com

SOURCE Attilio One

Share this article

Sandip Kapadia appointed Chief Financial Officer with more than 30 years of life sciences experience in growth strategy, capital formation and commercial execution

Eric Sievers, M.D., appointed Chief Medical Officer with more than 30 years of experience leading oncology clinical and translational research with a focus on antibody-drug conjugates

LOS ANGELES, Oct. 16, 2026 /PRNewswire/ -- TORL BioTherapeutics LLC ("TORL" or the "Company"), a clinical-stage oncology company, today announced the appointments of Sandip Kapadia as Chief Financial Officer and Eric Sievers, M.D., as Chief Medical Officer. These appointments complete a year-long strategic initiative to expand and strengthen TORL's leadership team as the Company advances its novel portfolio of antibody-based therapeutics toward late-stage development and potential commercialization.

Mr. Kapadia brings more than 30 years of life sciences experience with a strong track record in growth strategy, capital formation and commercial execution. Most recently, he served as Chief Financial and Administrative Officer at Harmony Biosciences during its transition to a profitable commercial-stage biotechnology company. He has raised more than $2 billion in public capital for emerging biotechnology companies.

Dr. Sievers's career spans more than three decades of clinical and translational research, with expertise in antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. Most recently, he served as Chief Medical Officer at BioAtla. His experience includes first-in-human studies, pivotal trials and regulatory submissions. Earlier in his career, he led clinical development of ADCETRIS from Investigational New Drug (IND) through initial Food and Drug Administration (FDA) approval. Dr. Sievers also served as a lead investigator in the first-in-human and pivotal trials supporting the initial approval of MYLOTARG.

"We are delighted to welcome Sandip and Eric to TORL at this important stage in our evolution. Together, they bring decades of leadership experience across the life sciences industry and a proven track record of advancing new therapeutics," said Aran Maree, M.D., Chief Executive Officer. "Sandip's strategic and financial leadership will be instrumental as we enter our next phase of growth, organizational scale and late-stage clinical development for our lead asset ixotatug vedotin (Ixo-V). Eric's experience advancing antibody therapeutics from early clinical development through regulatory approval will be invaluable as we advance Ixo-V and our broader pipeline. Their combined expertise further strengthens our ability to execute on the significant opportunity ahead. We look forward to working together as a leadership team to deliver on our mission to transform the lives of cancer patients with novel antibody-based therapies."

Separately, TORL announced that Mark Alles retired as Chairman of the Board at the end of September. Since joining TORL in 2022, Mr. Alles served in various leadership roles including as Board Manager, Chief Executive Officer and Chairman. During his tenure, he led the Company through a period of significant financial, clinical, and organizational growth and development. Mr. Alles will remain a strategic advisor to the Company.

"Mark has played an important role in TORL's evolution over the past several years," said Dr. Maree. "On behalf of the Board and management team, I want to thank him for his leadership, counsel and commitment to the Company. We are grateful that he will continue to support TORL as a strategic advisor."

About TORL BioTherapeutics LLC

TORL BioTherapeutics is a clinical-stage oncology company developing antibody-based therapeutics against first-in-world targets for solid tumors and hematologic cancers. Lead asset ixotatug vedotin (Ixo-V; TORL-1-23) is the first and only ADC that selectively targets Claudin 6 (CLDN6) with a proven monomethyl auristatin E (MMAE) linker-payload construct. Ixo-V is being evaluated in platinum-resistant ovarian cancer and other CLDN6-expressing cancers such as germ cell tumors and in various combinations. Ixo-V has been granted FDA Fast Track designation. The early pipeline includes the Phase 1 hematology asset TORL-5-700 and other undisclosed programs. TORL's unique discovery engine is enabled by a strategic partnership with the Slamon Research Lab at the University of California, Los Angeles (UCLA), which provides preferential access to novel cancer targets for therapeutic development. To date, TORL has raised more than $450 million from leading global biotechnology investors.

SOURCE TORL Biotherapeutics LLC

Share this article